News
Oral Anticoagulants Compared for Gastrointestinal Safety
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Your search for apixaban returned 26 results
News
AHA: Concentrates Promising for Reversal of Apixaban
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
News
Apixaban Seems Safer Than Rivaroxaban for A-Fib
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
News
Prophylaxis With Apixaban Feasible for Cancer Patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
News
Apixaban Beats Aspirin for Stroke Prevention in A-Fib
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
News
Safety of Direct Oral Anticoagulants Versus Warfarin Investigated
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
News
Lower Risk of CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
News
Many Patients Take OTC Meds That May Interact With Apixaban
Less knowledge about OTC products with potentially serious interactions linked to increased use
News
Apixaban vs Placebo in VTE Prevention in Cancer Patients Initiating Chemotherapy
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban vs placebo.
Drug News
Non-Vitamin K Oral Anticoagulants Vary in Assay Effects
Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.
